Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial: Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Apr 2. https://doi.org/10.1002/HEP.31843
In: Journal of Clinical and Experimental Hepatology, Jg. 12 (2022-03-01), Heft 2, S. 641-643
Online
academicJournal
Zugriff:
Titel: |
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial: Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Apr 2. https://doi.org/10.1002/HEP.31843
|
---|---|
Link: | |
Zeitschrift: | Journal of Clinical and Experimental Hepatology, Jg. 12 (2022-03-01), Heft 2, S. 641-643 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 0973-6883 (electronic) |
DOI: | 10.1016/j.jceh.2022.01.019 |
Sonstiges: |
|